HISAMITSU ADR

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2025, HISAMITSU ADR has already paid €0.15 in dividends. The last payout was in November 2025.

Financials

In the last quarter, HISAMITSU ADR had revenue of €263.28m and net profit of €39.46m

(EUR)	February 2026	YoY
Revenue	263.28m	-
Gross profit	145.92m	-
Net profit	39.46m	-
EBITDA	49.43m	-

Fundamentals

Metric	Value
Market capitalization	€748.98m
Number of shares	285.38m
52-week high/low	€8.41 - €2.62
Dividend yield	1.17%
Dividends TTM	€0.085
Beta	0.04
P/E ratio	22.44
PEG ratio	-2.49
P/B ratio	1.46
P/S ratio	2.61

Company profile

Hisamitsu Pharmaceutical Co., Inc. engages in the research, development, manufacture, and sale of pharmaceuticals and related products. Its products are sold under Salonpas, Salonsip, Mohrus, ByeBye-Fever, and Keplat brands. It also provides ethical pharmaceuticals, over- the-counter drugs, medical devices, health supplements, and topical analgesic products. The company was founded by Nihei Hisamitsu in 1847 and is headquartered in Tosu, Japan.